Dezheng Huo to Diphosphonates
This is a "connection" page, showing publications Dezheng Huo has written about Diphosphonates.
Connection Strength
0.213
-
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int. 2007 Jul; 100(1):70-5.
Score: 0.072
-
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology. 2007 Jul; 70(1):122-6.
Score: 0.072
-
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006 Sep; 176(3):972-8; discussion 978.
Score: 0.068